Patents by Inventor Janine Schuurman

Janine Schuurman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12247065
    Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 11, 2025
    Assignee: GENMAB A/S
    Inventors: Richard Hibbert, Rob De Jong, Aran Frank Labrijn, Arnout Gerritsen, Janine Schuurman, Paul Parren
  • Patent number: 12247080
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: March 11, 2025
    Assignee: GENMAB B.V.
    Inventors: Marije Overdijk, Kristin Strumane, Rik Rademaker, Esther Breij, Janine Schuurman, Paul Parren
  • Patent number: 12247077
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: March 11, 2025
    Assignee: Janssen Biotech, Inc.
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Publication number: 20250066506
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: March 5, 2024
    Publication date: February 27, 2025
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20250043018
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: June 12, 2024
    Publication date: February 6, 2025
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Aran Frank LABRIJN, Janine SCHUURMAN
  • Publication number: 20250002600
    Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: October 5, 2022
    Publication date: January 2, 2025
    Inventors: Alexander MUIK, Kristina SCHÖDEL, Nora PENCHEVA, Maria N. JURE-KUNKEL, Ugur SAHIN, Sina FELLERMEIER-KOPF, Patricia GARRIDO CASTRO, Jordan BLUM, Friederike GIESEKE, Esther C. W. BREIJ, Lars GUELEN, Joost NEIJSSEN, Karsten BECKMANN, Claudia PAULMANN, Bart-Jan DE KREUK, Richard G. HIBBERT, Janine SCHUURMAN, Aran LABRIJN, Ivan KUZMANOV
  • Patent number: 12173076
    Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: December 24, 2024
    Assignee: GENMAB B.V.
    Inventors: Frank Beurskens, Marije Overdijk, Annieck M. Diks, Rob De Jong, Kristin Strumane, Janine Schuurman, Paul Parren
  • Publication number: 20240327544
    Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: July 13, 2022
    Publication date: October 3, 2024
    Inventors: Ugur SAHIN, Alexander MUIK, Sina FELLERMEIER-KOPF, Yali FU, Homer ADAMS, III, Gaurav BAJAJ, Brandon HIGGS, Mark FERESHTEH, Vanessa SPIRES, Jordan BLUM, Patricia GARRIDO CASTRO, Michelle NIEWOOD, Friederike GIESEKE, Karsten BECKMANN, Claudia PAULMANN, Ivan KUZMANOV, Esther Cornelia Wilhelmina BREIJ, Lars GUELEN, Jost NEIJSSEN, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • Publication number: 20240317881
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: January 23, 2024
    Publication date: September 26, 2024
    Inventors: Bart DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • Publication number: 20240254252
    Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.
    Type: Application
    Filed: July 15, 2019
    Publication date: August 1, 2024
    Inventors: Bart E. C. G. DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David SATIJN, Tahamtan AHMADI
  • Patent number: 12049512
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: July 30, 2024
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • Publication number: 20240209117
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
    Type: Application
    Filed: November 13, 2023
    Publication date: June 27, 2024
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Edwald T. J. VAN DER BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20240150484
    Abstract: Described herein are proteins comprising an Fc region or the like, such as monoclonal, bispecific and multispecific antibodies, wherein the Fc region has been modified to eliminate or strongly reduce Fc-mediated effector functions, while at the same time allow for good developability, for therapeutic purposes and where such effector functions are undesired.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 9, 2024
    Inventors: Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran F. LABRIJN
  • Patent number: 11932693
    Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
    Type: Grant
    Filed: May 11, 2023
    Date of Patent: March 19, 2024
    Assignees: BioNTech SE, Genmab A/S
    Inventors: Ugur Sahin, Sina Fellermeier-Kopf, Friederike Gieseke, Karsten Beckmann, Claudia Paulmann, Alexander Muik, Ivan Kuzmanov, Esther Cornelia Wilhelmina Breij, Patricia Garrido Castro, Jordan Blum, Lars Guelen, Joost Neijssen, Bart-Jan De Kreuk, Richard Hibbert, Janine Schuurman, Aran Frank Labrijn
  • Publication number: 20240084036
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 14, 2024
    Inventors: Joost J. NEIJSSEN, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Patent number: 11866514
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: January 9, 2024
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Publication number: 20230374131
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: February 14, 2023
    Publication date: November 23, 2023
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Publication number: 20230365693
    Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Ugur SAHIN, Sina FELLERMEIER-KOPF, Friederike GIESEKE, Karsten BECKMANN, Claudia PAULMANN, Alexander MUIK, Ivan KUZMANOV, Esther Cornelia Wilhelmina BREIJ, Patricia GARRIDO CASTRO, Jordan BLUM, Lars GUELEN, Joost NEIJSSEN, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • Publication number: 20230322947
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Application
    Filed: September 22, 2022
    Publication date: October 12, 2023
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • Publication number: 20230310599
    Abstract: The present invention relates to combination therapy within the field of oncology; in particular to combination therapy with vaccines and binding agents binding to CD3 and to a target antigen on tumor cells.
    Type: Application
    Filed: September 2, 2021
    Publication date: October 5, 2023
    Inventors: Hreinn BENONISSON, Jim MIDDELBURG, Thorbald VAN HALL, Isil ALTINTAS, Kristel KEMPER, Janine SCHUURMAN, Katy Ann LLOYD, Vitalijs OVCINNIKOVS, Gijsbertus ZOM